Dr. William J. Howitt, MD
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 25
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
MO license 36287 -
Emergency Medicine Physician
MO license 36287
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 25
- Services billed
- 44
- Patients’ average age
- 63
| Service | Times | Patients |
|---|---|---|
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 114 | 29 |
| Established patient office or other outpatient visit, 20-29 minutes | 81 | 52 |
| Established patient office or other outpatient visit, 30-39 minutes | 55 | 39 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 12 | 12 |
| Annual alcohol misuse screening, 5 to 15 minutes | 11 | 11 |
| Annual depression screening, 5 to 15 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Springfield, MO | 112 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Springfield, MO | 71 |
| Pregabalin Other prescribers in Springfield, MO | 60 |
| Alprazolam Other prescribers in Springfield, MO | 57 |
| Tramadol Hcl Other prescribers in Springfield, MO | 41 |
| Omeprazole Other prescribers in Springfield, MO | 41 |
| Diazepam Other prescribers in Springfield, MO | 38 |
| Amlodipine Besylate Other prescribers in Springfield, MO | 35 |
| Oxycodone Hcl Other prescribers in Springfield, MO | 34 |
| Sertraline Hcl Other prescribers in Springfield, MO | 25 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 3 companies. The companies reported $12,700,600 in research payments for these studies, mostly to the institutions running them.
- A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
Eli Lilly and Company · Completed · NCT06440980 - A Study of LY3537031 in Overweight, Obese, and Healthy Participants
Eli Lilly and Company · Active, not recruiting · NCT06606106 - A Phase 1 Clinical Study in Healthy Females of Nonchildbearing Potential to Compare the Pharmacokinetics of Sotatercept MK-7962 Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation
Merck Sharp & Dohme LLC - Screening Protocol for Epstein-Barr Virus Vaccine Studies
Merck Sharp & Dohme LLC - A phase 3 protocol to investigate the safety tolerability and immunogenicity of BNT162B2 rnabased variantadapted vaccine candidates against SARSCOV2 in participants 12 through 64 years of age considered at higher risk…
Pfizer Inc. - A phase 23 protocol to investigate the safety tolerability and immunogenicity of BNT162B2 rnabased vaccine candidates for SARSCOV2 new variants in healthy individuals
Pfizer Inc. - A phase 3 study to evaluate the safety tolerability and immunogenicity of a respiratory syncytial virus rsv prefusion f subunit vaccine in adults 60 years of age and older
Pfizer Inc. - A phase 1 randomized doubleblind sponsoropen study to describe the safety and tolerability of a multivalent pneumococcal conjugate vaccine in adults
Pfizer Inc. - A phase 12 randomized observerblinded study to evaluate the safety tolerability and immunogenicity of combined vaccine candidates against influenza and COVID19 in healthy individuals
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.